This is the Nexus Narcolepsy registry, a joint venture of Jazz Pharmaceuticals, Narcolepsy Network, and Wake Up Narcolepsy. See ClinicalTrials.gov. NOW RECRUITING people with narcolepsy INTERNATIONALLY: CLICK HERE to register.
NOW RECRUITING people with narcolepsy in the U.S.: CLICK HERE. This is a Phase 2 clinical trial of SUVN-G3031, which is a histamine H3 receptor inverse agonist (similar to pitolisant). Preclinical information can be found HERE.
NOW RECRUITING adults age 18-60 with myotonic dystrophy type 1 (DM1), in the U.S: CLICK HERE. DM1 is often associated with hypersomnia. The study purpose is to evaluate the safety and tolerability of ERX-963 and its potential use as a treatment to reduce excessive daytime sleepiness / hypersomnia and improve cognitive function in DM1 participants compared to placebo treatment.
NOW RECRUITING people age 10 and older with narcolepsy type 1, in France: CLICK HERE. The goal is “to study the cerebral microglial activation in PET in NT1 patients with recent evolution (appearance of the first symptoms – somnolence and cataplexy – less than 2 years ago) in comparison with controls; then analyze the effect of age, and the severity of symptoms on this PET imaging biomarker.”
NOW RECRUITING adults age 18-80 in France: CLICK HERE.
NOW RECRUITING at Tangdu Hospital in Xi’an, Shaanxi Province, China: CLICK HERE.
NOT YET RECRUITING adults ages 18-65 with a diagnosis of narcolepsy type 1 in N. America and Japan: CLICK HERE. The purpose of this study is to assess the safety and tolerability of TAK-994 (an oral selective orexin-receptor agonist) following multiple doses in participants with NT1. The overall duration of the study is 35 days and participants will be followed up to 7 days after the last dose of study drug.
NOT YET RECRUITING children and adults with narcolepsy type 1, in France: CLICK HERE. This study proposes “to establish a comprehensive inventory of educational and professional trajectories of narcoleptic patients in France in order assess the specificity of the difficulties encountered by the people concerned in their life course and to appreciate the attitude of the academic and professional circle with respect to the disease.”
See XW Labs Initiates First-in-Human Phase I Study for Novel Narcolepsy Treatment. More information at the Australian New Zealand Clinical Trials Registry.